Brief: Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio

Sage Therapeutics

16/06/2025 12:43

June 16 (Reuters) - Supernus Pharmaceuticals Inc SUPN.O:

SUPERNUS PHARMACEUTICALS TO ACQUIRE SAGE THERAPEUTICS, STRENGTHENING ITS NEUROPSYCHIATRY PRODUCT PORTFOLIO

UPFRONT CASH PAYMENT OF $8.50 PER SHARE

EXPECTED TO BE SIGNIFICANTLY ACCRETIVE IN 2026 WITH POTENTIAL COST SYNERGIES OF UP TO $200 MILLION ON AN ANNUAL BASIS

DEALFOR AN AGGREGATE OF UP TO APPROXIMATELY $795 MILLION OR $12.00 PER SHARE

Source text: ID:nGNX1DFSm7

Further company coverage: SUPN.O

 ((Reuters.Briefs@thomsonreuters.com;))